You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial

Citation Tools

Article menu

Download PDFPDF

Miscellaneous
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
De Jaeghere EA, Tuyaerts S, van Nuffel AM, et al
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial
International Journal of Gynecologic Cancer 2022;32:A187-A188.